Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BHV-1510 |
| Synonyms | |
| Therapy Description |
BHV-1510 (PBI-410) is an antibody-drug conjugate (ADC) comprising an antibody targeting TROP2 linked to a camptothecin analogue, which potentially induces cytotoxicity against TROP2-expressing tumor cells and antitumor activity (Cancer Res (2024) 84 (6_Supplement): 7168; Cancer Res (2023) 83 (7_Supplement): 1549). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BHV-1510 | PBI 410|PBI410|GQ1010|GQ-1010|GQ 1010|PBI-410|BHV1510|BHV 1510 | TROP2 Antibody 18 | BHV-1510 (PBI-410) is an antibody-drug conjugate (ADC) comprising an antibody targeting TROP2 linked to a camptothecin analogue, which potentially induces cytotoxicity against TROP2-expressing tumor cells and antitumor activity (Cancer Res (2024) 84 (6_Supplement): 7168; Cancer Res (2023) 83 (7_Supplement): 1549). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06384807 | Phase Ib/II | BHV-1510 BHV-1510 + Cemiplimab | A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors | Recruiting | USA | 0 |